231 related articles for article (PubMed ID: 18051781)
21. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.
Lieber A; He CY; Kirillova I; Kay MA
J Virol; 1996 Dec; 70(12):8944-60. PubMed ID: 8971024
[TBL] [Abstract][Full Text] [Related]
22. Development of a packaging cell line for propagation of replication-deficient adenovirus vector.
Kim JS; Lee SH; Cho YS; Park K; Kim YH; Lee JH
Exp Mol Med; 2001 Sep; 33(3):145-9. PubMed ID: 11642550
[TBL] [Abstract][Full Text] [Related]
23. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit.
Yeh P; Dedieu JF; Orsini C; Vigne E; Denefle P; Perricaudet M
J Virol; 1996 Jan; 70(1):559-65. PubMed ID: 8523570
[TBL] [Abstract][Full Text] [Related]
24. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions.
Wang Q; Jia XC; Finer MH
Gene Ther; 1995 Dec; 2(10):775-83. PubMed ID: 8750018
[TBL] [Abstract][Full Text] [Related]
25. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
[TBL] [Abstract][Full Text] [Related]
26. Construction of adenoviral vectors.
Davis AR; Wivel NA; Palladino JL; Tao L; Wilson JM
Mol Biotechnol; 2001 May; 18(1):63-70. PubMed ID: 11439700
[TBL] [Abstract][Full Text] [Related]
27. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants.
Krougliak V; Graham FL
Hum Gene Ther; 1995 Dec; 6(12):1575-86. PubMed ID: 8664382
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence.
Hehir KM; Armentano D; Cardoza LM; Choquette TL; Berthelette PB; White GA; Couture LA; Everton MB; Keegan J; Martin JM; Pratt DA; Smith MP; Smith AE; Wadsworth SC
J Virol; 1996 Dec; 70(12):8459-67. PubMed ID: 8970968
[TBL] [Abstract][Full Text] [Related]
29. Human adenovirus type 35: nucleotide sequence and vector development.
Gao W; Robbins PD; Gambotto A
Gene Ther; 2003 Nov; 10(23):1941-9. PubMed ID: 14528318
[TBL] [Abstract][Full Text] [Related]
30. A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication.
Bernt K; Liang M; Ye X; Ni S; Li ZY; Ye SL; Hu F; Lieber A
J Virol; 2002 Nov; 76(21):10994-1002. PubMed ID: 12368342
[TBL] [Abstract][Full Text] [Related]
31. Rescue of chimeric adenoviral vectors to expand the serotype repertoire.
Roy S; Clawson DS; Lavrukhin O; Sandhu A; Miller J; Wilson JM
J Virol Methods; 2007 Apr; 141(1):14-21. PubMed ID: 17197043
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors.
Roy S; Gao G; Lu Y; Zhou X; Lock M; Calcedo R; Wilson JM
Hum Gene Ther; 2004 May; 15(5):519-30. PubMed ID: 15144581
[TBL] [Abstract][Full Text] [Related]
33. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors.
Kolls JK; Lei D; Odom G; Nelson S; Summer WR; Gerber MA; Shellito JE
Hum Gene Ther; 1996 Mar; 7(4):489-97. PubMed ID: 8800743
[TBL] [Abstract][Full Text] [Related]
34. Rapid construction of small interfering RNA-expressing adenoviral vectors on the basis of direct cloning of short hairpin RNA-coding DNAs.
Mizuguchi H; Funakoshi N; Hosono T; Sakurai F; Kawabata K; Yamaguchi T; Hayakawa T
Hum Gene Ther; 2007 Jan; 18(1):74-80. PubMed ID: 17187476
[TBL] [Abstract][Full Text] [Related]
35. Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro.
Aoki K; Barker C; Danthinne X; Imperiale MJ; Nabel GJ
Mol Med; 1999 Apr; 5(4):224-31. PubMed ID: 10448644
[TBL] [Abstract][Full Text] [Related]
36. Generation of recombinant adenovirus using the Escherichia coli BJ5183 recombination system.
Reddy PS; Ganesh S; Hawkins L; Idamakanti N
Methods Mol Med; 2007; 130():61-8. PubMed ID: 17401164
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.
Lusky M; Christ M; Rittner K; Dieterle A; Dreyer D; Mourot B; Schultz H; Stoeckel F; Pavirani A; Mehtali M
J Virol; 1998 Mar; 72(3):2022-32. PubMed ID: 9499056
[TBL] [Abstract][Full Text] [Related]
38. Development of an AdEasy-based system to produce first- and second-generation adenoviral vectors with tropism for CAR- or CD46-positive cells.
Janssen JM; Liu J; Skokan J; Gonçalves MA; de Vries AA
J Gene Med; 2013 Jan; 15(1):1-11. PubMed ID: 23225636
[TBL] [Abstract][Full Text] [Related]
39. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
Sakurai F; Kawabata K; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2005 Oct; 12(19):1424-33. PubMed ID: 15944730
[TBL] [Abstract][Full Text] [Related]
40. New tools for the generation of E1- and/or E3-substituted adenoviral vectors.
Danthinne X; Werth E
Gene Ther; 2000 Jan; 7(1):80-7. PubMed ID: 10680020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
